Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01853748
Title T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel + Trastuzumab

Ado-trastuzumab emtansine

Age Groups: adult
Covered Countries USA


No variant requirements are available.